In the same year, Falk et al., (2015) have examined the frequency and impact of TP53 and MDM2-309T>G polymorphism on treatment outcome and overall survival (OS) in 189 AML patients in Swedish people. This evidence concerns the gene TP53 and acute myeloid leukemia.